Therapeutic Application of Nanotechnology in Arteriosclerosis and Atherosclerosis

Dear Colleagues,

Atherosclerosis (AS) is a predominant risk factor for cardiovascular diseases (CVDs). The conventional treatments for AS include lipid-lowering, anti-inflammatory, and antiproliferative drugs. Though these show inhibitory effects on the development of AS, CVDs remain the leading cause of morbidity and mortality worldwide. Therefore, there is an urgent need to tackle AS from different angles to develop novel and more effective therapies. The utilization of nanotechnology for medical purposes has grown exponentially over the past few decades. Compared with conventional treatments, nanoparticle drugs exhibit significant advantages, including increased plaque-targeted drug delivery, sustained drug release, enhanced bioavailability, decreased toxicity, etc. This approach may be particularly useful in peripheral artery disease (PAD), where established cardiovascular therapies have not demonstrated local benefit in atherosclerotic burden or limb function. In addition, the collaborative treatment of nanoparticles with physical treatment (e.g., ultrasound, near-infrared lasers, and external magnetic field) also presents extra benefits in impeding the progression of AS.

This Special Issue aims to develop new insights into the perspective of nanotechnology in AS, discover new mechanisms/nano-drugs, and boost the clinically translational application of nanotechnology in CVDs, particularly PAD. Manuscripts from original research papers, comprehensive reviews, communications, and case reports are welcomed.

Dr. Luke Brewster
Dr. Fujie Zhao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• atherosclerosis
• nanoparticle
• targeted delivery
• therapeutic effect
• peripheral artery disease